Skip to main content

Advertisement

SpringerLink
Log in

Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the prognostic indicators, including clinicopathological and preoperative hematological factors, in patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and to develop a prognostic factor-based risk stratification model.

Methods

The clinicopathological data and preoperative parameters were collected from 345 UTUC patients treated with RNU without neoadjuvant therapy, retrospectively. The prognostic values of preoperative hematological parameters and clinicopathological factors were evaluated. Then, a risk stratification model was developed to predict poor survival after RNU using the regression coefficients of multivariate analysis.

Results

In multivariate analysis, high serum C-reactive protein (CRP) levels (≥0.5 mg/dl), low estimated glomerular filtration rate (eGFR) levels (<50 ml/min/1.73 m2), Eastern Cooperative Oncology Group Performance status ≥1, number of tumor foci >1, tumor grade (G3), positive LN, and positive surgical margin were independent factors predicting poor cancer-specific survival (CSS). Patients were stratified into three groups, and the risk stratification model revealed significant differences in CSS between the three subgroups. The 5-year CSS in patients at low, intermediate, and high risk was 92.7, 75.4, and 31.5 %, respectively.

Conclusion

This study indicates that preoperative hematological markers, such as low eGFR and high CRP levels predict a poor survival in patients with UTUC. Our risk stratification model may provide physicians with useful prognostic information for identifying patients who may be candidates for multimodal treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2009) Surveillance of urothelial carcinoma: stage and grade migration, 1993–2005 and survival trends, 1993–2000. Cancer 115(7):1435–1447. doi:10.1002/cncr.24147

    Article  PubMed  Google Scholar 

  2. Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernandez MI, Wood CG, Montorsi F, Strobel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57(4):575–581. doi:10.1016/j.eururo.2009.11.035

    Article  PubMed  Google Scholar 

  3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52(4):594–601

    Article  CAS  PubMed  Google Scholar 

  4. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58(4):574–580. doi:10.1016/j.eururo.2010.07.003

    Article  PubMed Central  PubMed  Google Scholar 

  5. Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martinez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G (2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol 29(4):487–494. doi:10.1007/s00345-011-0645-8

    Article  PubMed  Google Scholar 

  6. Cho KS, Hong SJ, Cho NH, Choi YD (2007) Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology 70(4):662–666. doi:10.1016/j.urology.2007.06.1106

    Article  PubMed  Google Scholar 

  7. Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF (2012) Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. J Urol. doi:10.1016/j.juro.2012.04.009

    Google Scholar 

  8. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martinez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071. doi:10.1016/j.eururo.2009.12.029

    Article  PubMed  Google Scholar 

  9. Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH (2009) The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol 182(2):451–458. doi:10.1016/j.juro.2009.04.026 (discussion 458)

    Article  PubMed  Google Scholar 

  10. Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100(2):269–273. doi:10.1111/j.1464-410X.2007.06934.x

    Article  CAS  PubMed  Google Scholar 

  11. Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G (2012) Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 109(8):1155–1161. doi:10.1111/j.1464-410X.2011.10479.x

    Article  PubMed  Google Scholar 

  12. Sengelov L, Kamby C, Schou G, von der Maase H (1994) Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74(1):123–133

    Article  CAS  PubMed  Google Scholar 

  13. Morizane S, Iwamoto H, Masago T, Yao A, Isoyama T, Sejima T, Takenaka A (2013) Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 45(1):99–106. doi:10.1007/s11255-012-0347-1

    Article  PubMed  Google Scholar 

  14. Suyama T, Nakajima K, Kanbe S, Tanaka N, Hara H, Ishii N (2011) Prognostic significance of preoperative serum CYFRA 21-1 in patients with upper urinary tract urothelial carcinoma. Int J Urol 18(1):43–47. doi:10.1111/j.1442-2042.2010.02671.x

    Article  CAS  PubMed  Google Scholar 

  15. The Japanese Urological Association TJSoP, Japan Radiological Society (2011) General rule for clinical and pathological studies on renal pelvic, ureteral and bladder cancer, 1st edn. Kanehara & Co., Ltd., Tokyo

    Google Scholar 

  16. Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 28(8):497–501

    Article  CAS  PubMed  Google Scholar 

  17. Inamoto T, Komura K, Watsuji T, Azuma H (2012) Specific body mass index cut-off value in relation to survival of patients with upper urinary tract urothelial carcinomas. Int J Clin Oncol 17(3):256–262. doi:10.1007/s10147-011-0284-5

    Article  PubMed  Google Scholar 

  18. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61(4):818–825. doi:10.1016/j.eururo.2012.01.021

    Article  PubMed  Google Scholar 

  19. Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF, French National Databaseon Upper Tract T, Upper Tract Urothelial Carcinoma C (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 189(5):1662–1669. doi:10.1016/j.juro.2012.10.057

    Article  PubMed  Google Scholar 

  20. Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA, Pignot G, Crouzet S, Rozet F, Neuzillet Y, Soulie M, Bodin T, Valeri A, Cussenot O, Roupret M, French collaborative national database on U-U (2012) Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer 106(6):1083–1088. doi:10.1038/bjc.2012.64

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Fromont G, Roupret M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O (2005) Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48(5):764–770. doi:10.1016/j.eururo.2005.07.005

    Article  CAS  PubMed  Google Scholar 

  22. Eltz S, Comperat E, Cussenot O, Roupret M (2008) Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int 102(5):532–535. doi:10.1111/j.1464-410X.2008.07659.x

    Article  CAS  PubMed  Google Scholar 

  23. Huang PC, Huang CY, Huang SW, Lai MK, Yu HJ, Chen J, Pu YS (2006) High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan. Int J Urol 13(7):864–869. doi:10.1111/j.1442-2042.2006.01429.x

    Article  PubMed  Google Scholar 

  24. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, Lorusso V, Guida M (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173(1):52–55. doi:10.1097/01.ju.0000146713.50673.e5

    Article  CAS  PubMed  Google Scholar 

  25. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K (2008) C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 101(8):978–981. doi:10.1111/j.1464-410X.2007.07408.x

    Article  PubMed  Google Scholar 

  26. Pierce BL, Neuhouser ML, Wener MH, Bernstein L, Baumgartner RN, Ballard-Barbash R, Gilliland FD, Baumgartner KB, Sorensen B, McTiernan A, Ulrich CM (2009) Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 114(1):155–167. doi:10.1007/s10549-008-9985-5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90(2):215–219. doi:10.1002/bjs.4038

    Article  CAS  PubMed  Google Scholar 

  28. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, Hofman A, Pols HA, Stricker BH (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24(33):5216–5222. doi:10.1200/JCO.2006.07.1381

    Article  CAS  PubMed  Google Scholar 

  29. Colin P, Ouzzane A, Yates DR, Francois A, Pignot G, Arvin-Berod A, Merigot de Treigny O, Laurent G, Valeri A, Jacques I, Saint F, Gardic S, Gres P, Rozet F, Neuzillet Y, Ruffion A, Roupret M (2012) Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 19(11):3613–3620. doi:10.1245/s10434-012-2453-9

    Article  PubMed  Google Scholar 

  30. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794–1799

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8504, Japan

    Shuichi Morizane, Tetsuya Yumioka, Noriya Yamaguchi, Toshihiko Masago, Masashi Honda, Takehiro Sejima & Atsushi Takenaka

Authors
  1. Shuichi Morizane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Yumioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noriya Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihiko Masago
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masashi Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takehiro Sejima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takehiro Sejima.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study received ethical approval from the Institutional Review Board of Tottori University Faculty of Medicine.

Informed consent

Informed consent was not obtained due to the retrospective nature of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morizane, S., Yumioka, T., Yamaguchi, N. et al. Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. Int Urol Nephrol 47, 1335–1341 (2015). https://doi.org/10.1007/s11255-015-1033-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1033-x

Keywords

Search

Navigation